Trial record 6 of 74 for:    MDV3100

Hepatic Impairment Study With MDV3100 in Subjects With Mild and Moderate Hepatic Impairment Compared to a Healthy Control Group

This study has been completed.
Sponsor:
Collaborator:
Medivation, Inc.
Information provided by (Responsible Party):
Astellas Pharma Inc ( Astellas Pharma Europe B.V. )
ClinicalTrials.gov Identifier:
NCT01901133
First received: June 18, 2013
Last updated: July 15, 2013
Last verified: July 2013
  Purpose

This study will assess the influence of hepatic impairment on the pharmacokinetics, safety and tolerability of a single dose of MDV3100 in male subjects.

The study will consist of two treatment arms. Arm A will assess the influence of mild hepatic impairment, and Arm B will assess the influence of moderate hepatic impairment. Data obtained from subjects with hepatic impairment will be compared to data from Body Mass Index (BMI) and age-matched subjects with normal hepatic function.


Condition Intervention Phase
Pharmacokinetics of MDV3100
Healthy Subjects
Kidney Diseases
Drug: MDV3100
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Parallel Assignment
Masking: Open Label
Official Title: A Phase I, Non-randomized, Open-label, Single-dose Study to Investigate the Pharmacokinetics, Safety and Tolerability of MDV3100 in Male Subjects With Mild or Moderate Hepatic Impairment and Normal Hepatic Function

Resource links provided by NLM:


Further study details as provided by Astellas Pharma Inc:

Primary Outcome Measures:
  • Assessment of pharmacokinetics measured by AUC0-inf following single dose of MDV3100 [ Time Frame: Day 1 through Day 50 (25 times) ] [ Designated as safety issue: No ]
    Area under the plasma concentration - time curve extrapolated to infinity (AUC0-inf) in subjects with mild and moderate hepatic impairment to matched control subjects with normal hepatic function.

  • Assessment of pharmacokinetics measured by Cmax following single dose of MDV3100 [ Time Frame: Day 1 through Day 50 (25 times) ] [ Designated as safety issue: No ]
    Maximum concentration (observed) (Cmax) in subjects with mild and moderate hepatic impairment to matched control subjects with normal hepatic function.


Secondary Outcome Measures:
  • Composite of pharmacokinetics following single dose of MDV3100 [ Time Frame: Day 1 through Day 50 (25 times) ] [ Designated as safety issue: No ]
    Measured by Time to attain Cmax (tmax), AUC up to last quantifiable concentration (AUC0-last), Apparent terminal elimination half life (t1/2), Apparent volume of distribution during the terminal phase after extra vascular dosing (Vz/F), Apparent total body clearance after extra vascular dosing (CL/F), Cmax, t1/2, AUC0-inf, Unbound maximum concentration (observed) (Cmax,u), Unbound AUC extrapolated to infinity (AUC0-inf,u), Unbound apparent total body clearance after extra vascular dosing (CLu/F), Unbound apparent volume of distribution during the terminal phase after extra vascular dosing (Vz,u/F), Fraction unbound (fu).

  • Monitoring of safety and tolerability through assessment of vital signs, Electrocardiogram (ECG) and clinical safety laboratory and adverse events [ Time Frame: Day 1 through Day 50 ] [ Designated as safety issue: Yes ]
    For hepatic impaired subjects, additional Child-Pugh classification will be performed after MDV3100 administration.


Enrollment: 33
Study Start Date: October 2011
Study Completion Date: January 2012
Primary Completion Date: January 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A: Mild hepatic impairment subjects + control Drug: MDV3100
Oral
Other Names:
  • Xtandi
  • enzalutamide
Experimental: B: Moderate hepatic impairment subjects + control Drug: MDV3100
Oral
Other Names:
  • Xtandi
  • enzalutamide

  Eligibility

Ages Eligible for Study:   18 Years to 69 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • All subjects must meet all of the following inclusion criteria:

    • Subject must be non-fertile, i.e., surgically sterilized or must practice an adequate contraceptive method to prevent pregnancies
    • Body Mass Index (BMI) of at least 18.5 and no greater than 34.0 kg/m2.
  • Subjects with mild or moderate hepatic impairment must also meet the following inclusion criteria:

    • Child-Pugh classification Class A (mild, 5 or 6 points) or Class B (moderate, 7 to 9 points) liver function impairment.

Exclusion Criteria:

  • All subjects must not have any of the following characteristics:

    • Known or suspected hypersensitivity to MDV3100 or any components of the formulation used.
    • History of seizure or any condition that may predispose to seizure. Also history of loss of consciousness or transient ischemic attack within 12 months of enrollment (Day 1 visit).
    • Any clinically significant history of asthma, eczema, any other allergic condition or previous severe hypersensitivity to any drug (excluding non-active hay fever).
    • Abnormal pulse and/or blood pressure (BP) measurements at the pre-study visit as follows: Pulse <40 or >90 bpm; mean systolic BP >160 mmHg; mean diastolic BP >100 mmHg (BP measurements taken in triplicate after subject has been resting in supine position for 5 min; pulse will be measured
    • A QTcF interval of >450 ms after repeated measurements (consistently after duplicate measurements), a history of unexplained syncope, cardiac arrest, unexplained cardiac arrhythmias or torsades de pointes, structural heart disease, or a family history of Long QT Syndrome (LQTS).
    • Significant renal dysfunction (creatinine clearance below 60 mL/min, estimated according to the method of modification of diet in renal disease (MDRD) formula).
    • Regular use of any inducer of metabolism (e.g. barbiturates, rifampin) in the 3 months prior to admission to the Clinical Unit.
    • Participation in any clinical study within 3 months or participation in more than 3 clinical studies within 12 months, prior to the expected date of enrolment into the study, provided that the clinical study did not entail a biological compound with a long terminal half life.
  • For subjects with normal hepatic function:

    • Regular use of any prescribed or OTC (over-the-counter) drugs, which includes vitamins, natural and herbal remedies (e.g. St John's wort) and food supplements in the 4 weeks prior to admission to the Clinical Unit and use of any drugs in the 2 weeks prior to admission to the Clinical Unit, except for occasional use of paracetamol (up to 3 g/day).
    • Positive serology test for HBsAg, anti HAV (IgM), anti-HCV, anti-HIV-1 or anti-HIV-2.
  • For subjects with mild or moderate hepatic impairment:

    • Fluctuating or rapidly deteriorating hepatic function, as indicated by strongly varying or worsening of clinical and/or laboratory signs of hepatic impairment within the screening period. (e.g. advanced ascites, infection of ascites, fever, active gastrointestinal bleeding).
    • Change in dose regimen of medically required medication within the last two weeks before pre-study examination (allowed co-medication in patients), and/or the use of unallowed co-medication in the 3 weeks prior to admission to the clinical unit (not allowed: any known hepatic enzyme altering agents or compounds known to restrict metabolism).
    • Presence of a hepatocellular carcinoma, or an acute liver disease caused by an infection or drug toxicity.
    • Severe portal hypertension or surgical porto-systemic shunts, including TIPSS (Transjugular intrahepatic portosystemic shunt).
    • Biliary obstruction or other cause of hepatic impairment not related to parenchymal disorder and/or disease of the liver.
    • Signs of significant hepatic encephalopathy (Hepatic encephalopathy score >2).
    • Severe ascites and/or pleural effusion
    • Esophageal variceal bleeding in the medical history.
    • Thrombocyte level below 40x109/L and /or hemoglobin below 90 g/L.
    • Previous liver transplantation.
    • Positive serology test for, anti HAV (IgM), anti-HIV-1 or anti-HIV-2.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01901133

Locations
Moldova, Republic of
Arensia
Chisinau, Moldova, Republic of
Sponsors and Collaborators
Astellas Pharma Europe B.V.
Medivation, Inc.
Investigators
Study Chair: Operation Senior Research Manager Astellas Pharma Europe B.V.
  More Information

No publications provided

Responsible Party: Astellas Pharma Inc ( Astellas Pharma Europe B.V. )
ClinicalTrials.gov Identifier: NCT01901133     History of Changes
Other Study ID Numbers: 9785-CL-0009
Study First Received: June 18, 2013
Last Updated: July 15, 2013
Health Authority: Moldova: Ministry of Health

Keywords provided by Astellas Pharma Inc:
Phase 1
MDV3100
Hepatic Impairment
Kidney Diseases
Xtandi
enzalutamide

Additional relevant MeSH terms:
Kidney Diseases
Liver Diseases
Urologic Diseases
Digestive System Diseases

ClinicalTrials.gov processed this record on August 27, 2014